Michel Vounatsos, Biogen CEO (via YouTube)
Biogen yanks its Aduhelm application in Canada, days after celebrating the drug's 1-year anniversary in the US
Add Canada to the list of countries where Biogen’s controversial Alzheimer’s drug Aduhelm isn’t wanted by health officials.
The biotech announced on Thursday that it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
